Qian Zhang

Qian Zhang

Auto-generated profile, based on publicly available information

Qian Zhang

Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
PDF file
ZHZitian Huo
Zitian Huo
YDYaqi Duan
Yaqi Duan
DZDongdong Zhan
Dongdong Zhan
XXXizhen Xu
Xizhen Xu
NZNairen Zheng
Nairen Zheng
YWYi Wang
Yi Wang
Small cell lung cancer (SCLC) is a highly malignant and heterogeneous cancer with limited therapeutic options and prognosis prediction models. Here, we analyzed formalin-fixed, paraffin-embedded (FFPE) samples of surgical resections by proteomic profiling, and stratified SCLC into three proteomic subtypes (S-I, S-II, and S-III) with distinct clinical outcomes and chemotherapy responses. The proteomic subtyping was an independent prognostic factor and performed better than current tumor–node–metastasis or Veterans Administration Lung Study Group staging methods. The subtyping results could be further validated using FFPE biopsy samples from an independent cohort, extending the analysis to both surgical and biopsy samples. The signatures of the S-II subtype in particular suggested potential benefits from immunotherapy. Differentially overexpressed proteins in S-III, the worst prognostic subtype, allowed us to nominate potential therapeutic targets, indicating that patient selection may bring new hope for previously failed clinical trials. Finally, analysis of an independent cohort of SCLC patients who had received immunotherapy validated the prediction that the S-II patients had better progression-free survival and overall survival after first-line immunotherapy. Collectively, our study provides the rationale for future clinical investigations to validate the current findings for more accurate prognosis prediction and precise treatments.

20 February 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JFJingyu Feng
Jingyu Feng
QZQian Zhang
Qian Zhang
LLLi Luo
Li Luo
ZGZhichao Gu
Zhichao Gu
WLWen Liu
Wen Liu
HZHuafeng Zhang
Huafeng Zhang
NADPH is essential for cellular biosynthesis and redox balance in CD8 + T cells. Here, we demonstrate that the nonoxidative pentose phosphate pathway (non-oxPPP), mediated by transketolase (TKT) and transaldolase (TALDO1), is critical for CD8 + T cell activation, proliferation, and memory formation by maintaining NADPH homeostasis. Metabolomic profiling and isotopic tracing revealed upregulated non-oxPPP flux in effector (T eff ) and memory (T m ) CD8 + T cells, enabling a pentose cycle that amplifies NADPH yield and sustains metabolic fitness for T cell immunity. Genetic knockdown or pharmacological inhibition of Tkt or Taldo1 impaired NADPH production, leading to ribose-5-phosphate (R5P) accumulation, oxidative stress, reduced lipid synthesis, mitochondrial dysfunction, and compromised T eff cell proliferation, cytokine production, and antitumor efficacy. Conversely, enhancing non-oxPPP activity promoted T m differentiation, persistence, and recall responses. Targeting the non-oxPPP represents a promising strategy to enhance cancer immunotherapy and vaccine efficacy by bolstering T cell effector and memory responses.

7 December 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
QZQian Zhang
Qian Zhang
YDYuting Dong
Yuting Dong
MZMeidong Zhou
Meidong Zhou
YGYujuan Guo
Yujuan Guo
LLLiping Lou
Liping Lou
YDYaqi Duan
Yaqi Duan
Background. Insulinoma‐associated protein 1 (INSM1) has been identified as a nuclear marker of neuroendocrine tumors. Although INSM1 appears to be a subtle and specific biomarker for neuroendocrine tumor, its expression and clinicopathological significance in mesenchymal tumors remain unclear. Methods. We analyzed INSM1 mRNA level in GEO database and conducted immunohistological staining to detect the expression of INSM1 on 576 mesenchymal tumors from pathology department of Tongji Hospital. Results. At transcription level, INSM1 expression in AITL (angioimmunoblastic T‐cell lymphoma) was higher than their adjacent normal tissues as well as Hodgkin’s lymphoma. Moreover, INSM1 expression in well‐differentiated liposarcoma (WDLPS) was significantly higher than normal fat (P = 0.014) and dedifferentiated liposarcoma (DDLPS) (P = 0.0248). At protein level, the positive rate of INSM1 in AITL was 18/48 (47.4%), while in DDLPS was 9/20 (45%). INSM1 expression in AITL was significantly higher than Hodgkin’s lymphoma (P = 0.008). And INSM1 expression in WDLPS was significantly lower than DDLPS (P = 0.015). Conclusion. The combination of GEO data and immunohistochemistry data indicated that the expression level of INSM1 was higher in AITL compared with normal control, suggesting that INSM1 may be involved in pathogenesis of AITL. The abnormal expression of INSM1 was found in WDLPS, and the positive rate of INSM1 was higher in DDLPS than in WDLPS. INSM1 may be involved in the regulation of liposarcoma development. There were significant differences in the expression of INSM1 between AITL and Hodgkin’s lymphoma and WDLPS and DDLPS. These findings may assist in the differential diagnosis of these tumors when common markers are difficult to identify, enriching the diagnostic index system of mesenchymal tumors.